About Us

Our Mission

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, botulism, Ebola, anthrax and opioid overdose emergencies. We help prepare communities for today’s health challenges and tomorrow’s threats by:

  • Empowering the public with the resources to respond to an opioid overdose emergency
  • Delivering medical countermeasures to fight critical, even deadly, biological threats
  • Stepping up to help address emerging and infectious diseases

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Our History

  • 1998-2002
  • 2003-2007
  • 2008-2010
  • 2014-2017
  • 2018-2023
  • 2025
1998

Emergent opened for business, partnering with the U.S. government to supply BioThrax (Anthrax Vaccine Absorbed) for military members.

2001

Terror attacks and subsequent anthrax letter incidents call for increased production of BioThrax, the only FDA-licensed anthrax vaccine at the time.

Began development of CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted), previously known as AV7909.

2002
2003

Acquired first Maryland-based site in Gaithersburg.

2006

Emergent BioSolutions common stock begins trading on the New York Stock Exchange ($EBS).

2007

Received first multi-year contract for BioThrax (Anthrax Vaccine Absorbed) by the U.S. government.

2008

Received funding for CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) from the Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID).

2009

Acquired a manufacturing facility in Baltimore’s Bayview neighborhood.

Initiated Phase 1 study for CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted).

2010
2014

Acquired Cangene Corporation, a Canadian company based in Winnipeg, which has since become one of Emergent’s largest manufacturing sites.

2015

Acquired rights to auto-injector technology, growing our devices business.

2017

Acquired ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) and raxibacumab (a fully human monoclonal antibody).

2018

Acquired NARCAN® Nasal Spray (naloxone HCl).

2022

Acquired TEMBEXA® (brincidofovir) and announced collaboration with Ridgeback Therapeutics to expand availability of EbangaTM (Ansuvimab-zykl).

Received approval for over-the-counter designation for NARCAN® Nasal Spray; received U.S. FDA approval of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted).

2023
2025

Obtained commercial rights to KLOXXADO® (naloxone HCI) Nasal Spray 8 mg

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • Strategic Partnerships

    <span class=”TextRun SCXP125314969 BCX0″ lang=”EN-GB” xml:lang=”EN-GB” data-scheme-color=”@FFFFFF,0,” data-usefontface=”true” data-contrast=”none”><span class=”NormalTextRun SCXP125314969 BCX0″>We leverage our specialized in-house capabilities to support biopharma </span></span><span class=”TextRun SCXP125314969 BCX0″ lang=”EN-GB” xml:lang=”EN-GB” data-scheme-color=”@FFFFFF,0,” data-usefontface=”true” data-contrast=”none”><span class=”NormalTextRun SCXP125314969 BCX0″>innovators, governments and non-government organizations with their </span></span><span class=”TextRun SCXP125314969 BCX0″ lang=”EN-GB” xml:lang=”EN-GB” data-scheme-color=”@FFFFFF,0,” data-usefontface=”true” data-contrast=”none”><span class=”NormalTextRun SCXP125314969 BCX0″>development and manufacturing needs. </span></span><span class=”EOP SCXP125314969 BCX0″>​</span>

Our Culture and Values

Our culture is informed by our values and commitment to protecting and saving lives. For all the people touched by our work, we operate with an unwavering commitment to honesty, integrity, and quality.

LEARN MORE